Advertisement

Pediatric Surgery International

, Volume 23, Issue 3, pp 215–218 | Cite as

Intralesional administration of interferon A for the management of severe haemangiomas

  • C. KaselasEmail author
  • G. Tsikopoulos
  • G. Papouis
  • V. Kaselas
Original Article

Abstract

Intralesional administration of interferon alpha (INF-A) is a new approach in haemangiomas treatment that we electively apply to our patients. The aim of this study is to report the beneficial results of this new kind of therapy. Thirty-two patients with severe haemangiomas, 19 females and 13 males, were treated at our department from January 2000 to December 2004. All patients received INF-A intralesionally at a dose of 1–3 MIU/m2 of body surface once a day for the first week, and then once a week until completion of therapy. Reduction was evaluated after clinical and radiological measurement before, during and after completion of therapy and was graded as complete (>80%), significant (50–80%), medial (20–50%) and no response (<19%). Mean duration of therapy was 8 weeks (2 months). Most patients had not received prior therapy. Complete regression was noticed in 18 patients, satisfactory in 8 patients, minimal in 4 and no response in 2 patients. Minimal complications such as flu-like malaise with fever were reported by 23 patients at the beginning of therapy, but it was resolved easily by paracetamol administration. Complications such as haemorrhage or allergic reaction during administration or neurological symptoms were not reported or noticed. Intralesional administration of interferon A can be considered as a safe option for the management of massive or life-threatening haemangiomas as it requires reduced duration of treatment; hence this option results in reduced financial cost, is well tolerated by patients and is free of major complications.

Keywords

Haemangioma Interferon A Intralesional administration 

References

  1. 1.
    Silverman RA (1991) Hemangiomas and vascular malformations. Ped Clin North Am 38:811–834Google Scholar
  2. 2.
    Weber TR, Connors RH, Tracy TF, Bailey PV (1990) Complex hemangiomas of infants and children: individual management in 22 cases. Arch Surg 125:1017–1021PubMedGoogle Scholar
  3. 3.
    Chen MT, Yeong EW, Horug SY (2000) Intralesional corticosteroids therapy in proliferative head and neck hemangiomas: a review of 155 cases. J Ped Surg 35(3):420–423CrossRefGoogle Scholar
  4. 4.
    Moore J, Lee M, Gazzon M et al (2001) Effective therapy of a vascular tumor of infancy with vincristine. J Ped Surg 36(8):1273–1276CrossRefGoogle Scholar
  5. 5.
    Marler JJ, Rubin JB, Trede NS et al (2002) Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics 109(2):E37PubMedCrossRefGoogle Scholar
  6. 6.
    Miller SH, Smith RL, Schochut SJ (1976) Compression treatment of hemangiomas. Plast Surg 58:573–579Google Scholar
  7. 7.
    Goldwyn RM, Rosoff CB (1969) Cryosurgery for large hemangiomas in adults. Plast Reconstr Surg 43:605–611PubMedCrossRefGoogle Scholar
  8. 8.
    Riche MC, Hadjean E, Tran BH et al (1983) The treatment of capillary venous malformations using a new fibrosing agent. Plast Reconstr Surg 71:607–614PubMedCrossRefGoogle Scholar
  9. 9.
    Brouty-Boye D, Zetter B (1980) Inhibition of cell motility by interferon. Science 208:516–518PubMedCrossRefGoogle Scholar
  10. 10.
    Sidky Y, Borden EC (1987) Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte- induced vascular responses. Cancer Res 47:5155–5161PubMedGoogle Scholar
  11. 11.
    Lindner DJ (2002) Interferons as antiangiogenic agents. Curr Oncol Rep 4(6):510–514PubMedGoogle Scholar
  12. 12.
    Lloret P (2004) Medical treatment of haemangiomas. An Sist Sanit Navar 27(Suppl 1):81–92PubMedGoogle Scholar
  13. 13.
    Damas Mateache B, Menendez Suso JJ, Abelairas Gomez JM, Albajara Velasco L, Peralta Calvo J, Verdu Sanchez C, Royo Orejas A (2003) Interferon alpha and infantile orbital hemangioma. Arch Soc Esp Oftalmol 78(11):623–629PubMedCrossRefGoogle Scholar
  14. 14.
    Fledelius HC, Illum N, Jensen H, Prause JU (2001) Interferon-alfa treatment of facial infantile haemangiomas: with emphasis on the sight-threatening varieties. A clinical series. Acta Ophthalmol Scand 79(4):370–373PubMedCrossRefGoogle Scholar
  15. 15.
    Grimal I, Duveau E, Enjolras O, Verret JL, Ginies JL (2000) Effectiveness and dangers of interferon- alpha in the treatment of severe hemangiomas in infants. Arch Pediatr 7(2):163–167PubMedCrossRefGoogle Scholar
  16. 16.
    Schiavetti A, De Pasquale MD, Di Salvo S, Ventriglia F, Clerico A (2003) Recombinant interferon alfa 2a in hepatic hemangiomatosis with congestive heart failure: a case report. Pediatr Hematol Oncol 20(2):161–165PubMedCrossRefGoogle Scholar
  17. 17.
    Dubois J, Hershon L, Carmant L, Belanger S, Leclerc JM, David M (1999) Toxicity profile of interferon alfa-2b in children: a prospective evaluation. J Pediatr 135(6):782–785PubMedCrossRefGoogle Scholar
  18. 18.
    Garmendia G, Miranda N, Borosso S, Longchong M, Martinez E, Ferrero J, Porrero P, Lopez-Saura P (2001) Regression of infancy hemangiomas with recombinant IFN- alpha 2b. J Interferon Cytokine Res 21(1):31–38PubMedCrossRefGoogle Scholar
  19. 19.
    Tamayo L, Ortiz DM, Orozco-Covarrubias L, Duran-McKinster C, Mora MA, Avila E, Teixeira F, Ruiz-Maldonado R (1997) Therapeutic efficacy of interferon alfa-2b in infants with life threatening giant hemangiomas. Arch Dermatol 133(12):1567–1571PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • C. Kaselas
    • 1
    Email author
  • G. Tsikopoulos
    • 1
  • G. Papouis
    • 1
  • V. Kaselas
    • 1
  1. 1.Pediatric Surgery Department“Hippokration” General HospitalThessalonikiGreece

Personalised recommendations